drugset / Trial / NCT02023710

Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma

NCT02023710 ↗

Phase 2 Unknown 182 enrolled Peking University Cancer Hospital & Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

Mucosal melanoma is rare and associated with extremely poor prognosis.No effective treatment for advanced mucosal melanoma patients.Investigators conducted a randomized phase II study in patients with previously untreated metastatic mucosal melanoma to characterize the efficacy and safety of bevacizumab when combined with carboplatin plus paclitaxel.

Timeline

Start
2013-12
Primary completion
2017-12
Completion
2017-12

Outcome

Met primary endpoint

paper The median PFS was significantly longer in the CPB arm PMID 33444116 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications